PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31980842-9	2020	In addition, a PI3-kinase inhibitor and reduction in endogenous levels of the vitamin D receptor (VDR) by siRNA suppressed insulin- and 1,25(OH)2D-induced expression of Fam210a, respectively.	25-hydroxyvitamin D3-bromoacetate	136-146	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	78-96	
31980842-9	2020	In addition, a PI3-kinase inhibitor and reduction in endogenous levels of the vitamin D receptor (VDR) by siRNA suppressed insulin- and 1,25(OH)2D-induced expression of Fam210a, respectively.	25-hydroxyvitamin D3-bromoacetate	136-146	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	98-101	
31958633-1	2020	The vitamin D receptor (VDR) and its ligand 1,25(OH)2D3 (1,25D) impact differentiation and exert anti-tumor effects in many tissues, but its role in salivary gland has yet to be defined.	25-hydroxyvitamin D3-bromoacetate	57-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-22	
31958633-1	2020	The vitamin D receptor (VDR) and its ligand 1,25(OH)2D3 (1,25D) impact differentiation and exert anti-tumor effects in many tissues, but its role in salivary gland has yet to be defined.	25-hydroxyvitamin D3-bromoacetate	57-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	24-27	
31958633-8	2020	We demonstrated VDR expression and regulation of VDR target genes Vdr and Postn by 1,25D in mSGc, indicating functional ligand-mediated transcriptional activity.	25-hydroxyvitamin D3-bromoacetate	83-88	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	16-19	
31958633-8	2020	We demonstrated VDR expression and regulation of VDR target genes Vdr and Postn by 1,25D in mSGc, indicating functional ligand-mediated transcriptional activity.	25-hydroxyvitamin D3-bromoacetate	83-88	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	49-52	
31958633-8	2020	We demonstrated VDR expression and regulation of VDR target genes Vdr and Postn by 1,25D in mSGc, indicating functional ligand-mediated transcriptional activity.	25-hydroxyvitamin D3-bromoacetate	83-88	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	66-69	
31958633-9	2020	The effect of VDR signaling on epithelial differentiation markers was assessed by qPCR and IHC in mSGc cells treated with 1,25D.	25-hydroxyvitamin D3-bromoacetate	122-127	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	14-17	
31823770-1	2019	BACKGROUND: Recent evidence has suggested that the 1,25(OH)2D3/Vitamin D receptor (VDR) acts to suppress the immune response associated with systemic lupus erythematosus (SLE), a serious multisystem autoimmune disease.	25-hydroxyvitamin D3-bromoacetate	51-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	63-81	
31866009-0	2020	The 25(OH)D/VDR signaling may play a role in major depression.	25-hydroxyvitamin D3-bromoacetate	4-11	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	12-15	
31725940-4	2020	Using ChIP-PCR, EMSA assays and a luciferase reporter assay, we then demonstrated that 1,25(OH)2 D3 up-regulated Bmi1 expression at a transcriptional level via the VDR.	25-hydroxyvitamin D3-bromoacetate	87-99	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	164-167	
31881310-2	2020	Transepithelial intestinal Ca absorption is mediated by 1,25-dihydroxyvitamin D (1,25(OH)2D, calcitriol) through the vitamin D receptor (VDR).	25-hydroxyvitamin D3-bromoacetate	81-91	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	137-140	
31823770-2	2019	Hence, the aim of the current study was to investigate the mechanism by which 1,25-(OH)2D3/VDR influences SLE through regulating the Skp2/p27 signaling pathway.	25-hydroxyvitamin D3-bromoacetate	78-90	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	91-94	
31823770-1	2019	BACKGROUND: Recent evidence has suggested that the 1,25(OH)2D3/Vitamin D receptor (VDR) acts to suppress the immune response associated with systemic lupus erythematosus (SLE), a serious multisystem autoimmune disease.	25-hydroxyvitamin D3-bromoacetate	51-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	83-86	
31823770-8	2019	Notably, 1,25(OH)2D3/VDR mice had lower concentrations of BUN and Cr, urinary protein levels, precipitation intensity of the immune complex and complement, as well as the levels of anti-nRNP IgG and anti-dsDNA IgG in SLE mice.	25-hydroxyvitamin D3-bromoacetate	9-20	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	21-24	
31823770-10	2019	CONCLUSION: This study indicated that 1,25-(OH)2D3/VDR facilitated the recovery of SLE by downregulating Skp2 and upregulating p27 expression, suggesting the potential of 1,25-(OH)2D3/VDR as a promising target for SLE treatment.	25-hydroxyvitamin D3-bromoacetate	38-50	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	184-187	
31823770-10	2019	CONCLUSION: This study indicated that 1,25-(OH)2D3/VDR facilitated the recovery of SLE by downregulating Skp2 and upregulating p27 expression, suggesting the potential of 1,25-(OH)2D3/VDR as a promising target for SLE treatment.	25-hydroxyvitamin D3-bromoacetate	171-183	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	51-54	
31561249-8	2019	24R,25(OH)2D3 treatment resulted in increased plectin and integrin beta4 levels in VDR WT MPCEC, and decreased levels in VDR KO MPCEC.	25-hydroxyvitamin D3-bromoacetate	4-13	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	83-86	
31561249-8	2019	24R,25(OH)2D3 treatment resulted in increased plectin and integrin beta4 levels in VDR WT MPCEC, and decreased levels in VDR KO MPCEC.	25-hydroxyvitamin D3-bromoacetate	4-13	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	121-124	
31561249-13	2019	For hemidesmosome proteins, 24R,25(OH)2D3 increased plectin and integrin beta4 protein expression in VDR WT and HCEC, with decreased expression in VDR KO MPCEC.	25-hydroxyvitamin D3-bromoacetate	32-41	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	101-104